SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$46.56
-0.22 (-0.47%)
ā¼
5d:
+4.0%
30d:
-4.32%
90d:
-3.94%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: Apr 23, 2026
23d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ā BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
ā BUY SIGNAL: SNY shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$61.86
Based on 5.3% avg growth
INTRINSIC VALUE TODAY
$38.41
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $46.56, which is considered slightly high relative to its 30-day fair value range of $44.22 to $47.24. The stock's valuation (Forward PE: 8.8) is in line with its historical norms (9.0). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This pessimistic expectation contrasts with the company's recent 2.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is approaching resistance at $47.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.68 (+23.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SNY is in a strong downtrend. The price is approaching resistance at $47.83. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $57.68 (+23.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$44.22 -
$47.24
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
76.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.3% below Wall St target ($57.68)
Fair Price Analysis
30-Day Fair Range
$44.22 -
$47.24
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$43.32
Resistance Level
$47.83
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.79
Wall Street Target
$57.68
(+23.3%)
Revenue Growth (YoY)
6.9%
Earnings Growth (YoY)
2.4%
Profit Margin
16.7%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
8.8 vs 9.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$46.45
(-1%)
2-Year Target
$46.13
(-1%)
3-Year Target
$45.80
(-2%)
3-Yr Target (if PE normalizes)
(PE: 9ā9)
$46.90
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 6.5%)
$143.99
(+208%)
Base:
(SPY PE: 8.8, Growth: 6.5%)
$56.50
(+21%)
Bear:
(PE: 7.5, Growth: 6.5%)
$48.02
(+3%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 19.31 | Current EPS (TTM): $2.31
Bull Case
$98.12
(+119%)
Analyst growth 100.0%, PE expands to 21.2
Base Case
$89.20
(+99%)
Market implied 100.0%, PE stable at 19.3
Bear Case
$30.33
(-32%)
Severe decline -20.0%, PE contracts to 16.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
š”
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.8 to 9.0
Stabilization Target:
$47.90
(+2.4%)
PE Expansion Potential:
+2.4%
Share & Embed Analysis
Last updated: March 30, 2026 9:55 AM ET
Data refreshes hourly during market hours. Next update: 10:55 AM
Data refreshes hourly during market hours. Next update: 10:55 AM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 51 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 57 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 62 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$128 | 68 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 58 HOLD |
